Extended indication Cemiplimab is being investigated in recurrent, persistent, and/or metastatic cervical cancer (2L mon
Therapeutic value No estimate possible yet
Total cost 7,280,000.00
Registration phase Registration application pending


Active substance Cemiplimab
Domain Oncology and Hematology
Reason of inclusion Indication extension
Main indication Cervical cancer
Extended indication Cemiplimab is being investigated in recurrent, persistent, and/or metastatic cervical cancer (2L mono) with squamous cell histology, for which there is not a curative-intent option (surgery or radiation therapy with or without chemotherapy). Tumor progression or recurrence after treatment with platinum therapy (must have been used to treat metastatic, persistent, or recurrent cervical cancer).
Proprietary name Libtayo
Manufacturer Sanofi
Mechanism of action PD-1 / PD-L1 inhibitor
Route of administration Intravenous
Therapeutical formulation Infusion fluid
Budgetting framework Intermural (MSZ)
Additional comments PD-1 receptor antagonist


Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date November 2021
Expected Registration December 2022
Orphan drug No
Registration phase Registration application pending
Additional comments De fabrikant verwacht registratie rond december 2022.

Therapeutic value

Current treatment options Bevacizumab, chemotherapie.
Therapeutic value No estimate possible yet
Frequency of administration 1 times every 3 weeks
Dosage per administration 350 mg
References NCT03257267

Expected patient volume per year

Patient volume

< 80

Market share is generally not included unless otherwise stated.

References Horizonscan Geneesmiddelen; pembrolizumab + chemo (1L combo) cervical cancer, NKR 2019 incidentie baarmoederhalskanker
Additional comments Het cervixcarcinoom wordt in Nederland jaarlijks bij ongeveer 912 vrouwen vastgesteld. Er wordt verwacht dat er 70-80 patiënten in aanmerking zullen komen voor eerstelijnsbehandeling met pembrolizumab in combinatie met chemo. Voor de tweedelijn monotherapie cemiplimab komt hierdoor naar verwachting een deel van deze groep in aanmerking.

Expected cost per patient per year

Cost 91,000.00
References Lijstprijs zoals vermeld in de G-Standaard van Z-Index
Additional comments 1 maal per 3 weken €5.721,10 inclusief btw. dus €5.248,72 exclusief btw. Uitgaande van een heel behandeljaar zouden de kosten maximaal zo'n €91.000 betreffen.

Potential total cost per year

Total cost


This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions NSCLC
References Fabrikant

Other information

There is currently no futher information available.